Aptevo Therapeutics Inc. (APVO)

NASDAQ: APVO · IEX Real-Time Price · USD
3.01
-0.11 (-3.53%)
At close: Sep 27, 2022 3:58 PM
3.00
-0.01 (-0.33%)
After-hours: Sep 27, 2022 4:00 PM EDT
-3.53%
Market Cap 15.32M
Revenue (ttm) 9.88M
Net Income (ttm) 7.04M
Shares Out 5.09M
EPS (ttm) 1.15
PE Ratio 2.62
Forward PE 3.94
Dividend n/a
Ex-Dividend Date n/a
Volume 35,897
Open 3.06
Previous Close 3.12
Day's Range 3.00 - 3.33
52-Week Range 3.00 - 22.08
Beta 5.82
Analysts Buy
Price Target 18.36 (+510.0%)
Earnings Date Aug 11, 2022

About APVO

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a ... [Read more...]

Industry Biotechnology
Employees 54
Stock Exchange NASDAQ
Ticker Symbol APVO
Full Company Profile

Financial Performance

In 2021, APVO's revenue was $12.29 million, an increase of 185.26% compared to the previous year's $4.31 million. Losses were -$28.46 million, 60.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for APVO stock is "Buy." The 12-month stock price forecast is 18.36, which is an increase of 509.97% from the latest price.

Price Target
$18.36
(509.97% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

SEATTLE, WA / ACCESSWIRE / August 11, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therap...

1 month ago - Accesswire

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436...

Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date Cohort 3 Monotherapy Patient Achieved Bone Marrow Complete Remission Company Also Reports Myel...

3 months ago - Accesswire

Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeut...

4 months ago - Accesswire

APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting

Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant Disease SEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therap...

5 months ago - Accesswire

Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment ...

Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible Status SEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a cli...

5 months ago - Accesswire

Why Did Aptevo Therapeutics Stock Jump 25% Today?

Aptevo Therapeutics Inc (NASDAQ: APVO) shares are trading higher Thursday after the company reported 2021 financial results.  Aptevo said royalty revenue totaled $12.3 million in 2021, up from royalties...

6 months ago - Benzinga

Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update

SEATTLE, WA / ACCESSWIRE / March 24, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprieta...

6 months ago - Accesswire

Why Are Aptevo Therapeutics Shares Trading Higher Today?

Aptevo Therapeutics Inc APVO earned a $10 million non-dilutive milestone payment related to 2021 sales of Ruxience, under the terms of its royalty purchase agreement with HealthCare Royalty Management L...

7 months ago - Benzinga

Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update

APVO436 Phase 1b Trial for Acute Myeloid Leukemia Adds New Site Complete Remission Patient to Advance to Transplant SEATTLE, WA / ACCESSWIRE / February 9, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or th...

7 months ago - Accesswire

Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022

Vice Chairman, John E. Niederhuber, M.D.

8 months ago - Accesswire

Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication

LUND, Sweden and SEATTLE, Dec. 15, 2021 /PRNewswire/ -- Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ: APVO) today announced publication of an article in the December ...

9 months ago - PRNewsWire

Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"

LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / December 15, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced publication of an article in the De...

9 months ago - Accesswire

Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial

Aptevo Therapeutics Inc (NASDAQ: APVO) has announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML).  A high-risk AML patient treated in Cohort 1 ...

10 months ago - Benzinga

Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi ...

SEATTLE, WA / ACCESSWIRE / November 23, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology ther...

10 months ago - Accesswire

Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual...

SEATTLE, WA / ACCESSWIRE / November 15, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology ther...

10 months ago - Accesswire

Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights

SEATTLE, WA / ACCESSWIRE / November 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology ther...

10 months ago - Accesswire

Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021

Data support Advancement into the Clinic LUND, SWEDEN, and SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") today announce preclini...

10 months ago - Accesswire

Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cance...

Preclinical data demonstrates inhibited tumor cell growth in vitro when paired with a T-cell engager bispecific SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "...

10 months ago - Accesswire

Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtua...

SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology thera...

11 months ago - Accesswire

Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low...

SEATTLE, WA / ACCESSWIRE / October 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology thera...

11 months ago - Accesswire

Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging

Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for targ...

11 months ago - Accesswire

Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or M...

Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies Data was publ...

1 year ago - Accesswire

Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights

SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therap...

1 year ago - Accesswire

Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEG...

SEATTLE, WA / ACCESSWIRE / July 16, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its...

1 year ago - Accesswire

Aptevo Therapeutics' Scientists to Present At Virtual Cell Engager Summit

SEATTLE, WA / ACCESSWIRE / June 30, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its...

1 year ago - Accesswire